Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Coho who wrote (946)	5/18/1998 3:03:00 AM
From: Rob	Read Replies (1) of 1501

To all: The topic of this post is unrelated to IZP so please skip to the next note if so desired. I had the good fortune this past weekend to attend my alumni reunion in Boston. Dr. Judah Folkman was one of the guest speakers. As I'm sure everyone knows, this is the scientist working with angiogenesis inhibitors who recently appeared in the NY times and created a media circus. He presented data from his work and spoke about angiostatin and endostatin for about an hour. I had the opportunity to speak with Dr. Folkman after the conference and questioned him about several of the "hurdles" that I've frequently heard bandied about that would hinder a successful leap to man from his mouse model. I was blown away by this man's patient, frank answers. He's well aware of the obstacles that exist and believes them to be surmountable. This was not a hypester of the type that I could recognize. He keeps a journal of attributed quotes from M.D.'s , researchers, etc. of the "that'll never work" type. He dates them and then checks them off as further research disproves them. I think he said these quotes now number in the hundreds. He has offered to double the salary of any post-doc in his lab that can find a tumor that doesn't respond to these statins. Over 80 tumors have been tested as well as two leukemias, none have been unresponsive. No resistance develops because these proteins treat the mutation-resistant endothelial cells. My point is that anyone interested in biotechnology needs to watch what transpires at the end of this year. As of this weekend the FDA has approved compassionate use testing of angiostatin and endostatin on 30 patients commencing in December. If this stuff even comes close to functioning in humans the way it does in mice without significant human toxicity, the response will be global and immediate. Yes, I know mice aren't human etc.etc. and he knows that too. It turns out that wound healing (even more amazing) is apparently not inhibited by these statins because the vessels are different and respond to different factors. I don't currently have a position in Entremed (ENMD) but it merits some thought. Will Dr. Folkman pull the sword from the stone? Who knows. After listening to him and meeting him though, I think this guy definitely has the ability to surprise the hell out of a whole lot of naysayers. Maybe it was the glint in his eye. Rob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next